IMPROVING IBD CARE

IMPROVING IBD CARE: A PERSONALIZED APPROACH TO MANAGEMENT

PROGRAM Information

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with inflammatory bowel disease (IBD).

Educational Objectives

After completing this program, participants should be better able to:

Personalize treatment plans for patients based on risk of aggressive disease

Incorporate therapeutic drug monitoring-based strategies into clinical practice

Differentiate among various oral and IV iron formulations

Incorporate current clinical pathways for managing iron deficiency anemia in IBD effectively into clinical practice


Provided by

For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.

WEBCAST







(SELECT A SPEAKER TO VIEW THEIR BIO AND DISCLOSURE)

GARY R. LICHTENSTEIN, MD
(CHAIR)

MARIA T. ABREU, MD

EDWARD V. LOFTUS JR., MD

AGENDA


A Case-Based Approach to Personalizing Care in IBD


Optimizing Preventive Care for Patients with IBD


Panel Discussion / Extended Q&A


Adjournment

GARY R. LICHTENSTEIN, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

Back to Agenda

Gary R. Lichtenstein, MD, FACP, FACG, AGAF, is the director of the Inflammatory Bowel Disease Program in the Department of Medicine’s Division of Gastroenterology at the Hospital of the University of Pennsylvania, and a professor of medicine at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia, Pennsylvania.

Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in internal medicine at Duke University Medical Center in Durham, North Carolina. He also completed a fellowship in gastroenterology at the Hospital of the University of Pennsylvania in the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease, and he has received numerous research grants focusing on these areas. Dr. Lichtenstein has served as the national/international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn’s disease.

A fellow of the American Gastroenterological Association (AGA), the American College of Physicians, and the American College of Gastroenterology (ACG), Dr. Lichtenstein has been listed in Best Doctors in America (Inflammatory bowel disease), and has served as medical secretary for the gastroenterology section of the American Board of Internal Medicine. He holds membership and committee positions in many professional societies at a national level, including the AGA, where he has served as chair of the Clinical Practice Updates Committee and as vice chair of the Clinical Practice Updates Committee and the Practice Management Economics Committee; the American Society for Gastrointestinal Endoscopy, where he has served on the Committee on Training; and the ACG, where he has served on the Educational Affairs Committee, the programs committee, and the nominations committee, as well as recently serving as a member of the Research Committee.

Dr. Lichtenstein has also been the chair of the abstract review committee for Inflammatory bowel disease for the ACG. He is a member of the Crohn’s & Colitis Foundation of America (CCFA), where he served at the national level as the chair of the Membership Committee of the Clinical Research Alliance, on the national grants review committee, and on the national physician education committee. In addition, he is a longstanding member of the American College of Physicians and the American Medical Association.

Dr. Lichtenstein has received numerous awards in the University of Pennsylvania Health System, including the Louis Duhring Outstanding Clinical Specialist Award, the Lindback Award for Distinguished Teaching (the top teaching award at the University of Pennsylvania), and the Penn Pearls Award, the medical school teaching award. He has received the Department of Medicine Housestaff teaching award, the Donald B. Martin Teaching Service Award, and the Gastroenterology Division Sidney Cohen Teaching Award for Faculty. He is listed in The Best Doctors in America (Inflammatory bowel disease) and in Philadelphia Magazine as being among the top gastroenterologists for the elderly in Philadelphia and among the top gastroenterologists in Philadelphia (special focus: Inflammatory bowel disease). He is also the recipient of the CCFA Physician of the Year Award (Philadelphia/Delaware Valley Chapter).

In addition to having served on the editorial board of the journals Gastroenterology, the American Journal of Gastroenterology, Inflammatory Bowel Diseases, the World Journal of Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein has served as a former writer of selected summaries in the journal Gastroenterology, as the section editor of selected summaries, and as the section editor of print and media reviews in gastroenterology for a fie-year term. He has also served and currently serves as a reviewer for such journals as the New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine, Gut, the Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology, the World Journal of Gastroenterology, and the Journal of Clinical Gastroenterology. He is executive editor of the newly PubMed-indexed journal Gastroenterology & Hepatology, and serves as associate editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and the Journal of Clinical Investigation. He is currently assistant editor in chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international level, Dr. Lichtenstein is the author or coauthor of more than 250 peer-reviewed primary articles, chapters, letters, and editorials. He has presented over 250 abstracts and edited 18 books. He has lectured at a national and international level at more than 300 invited conferences, symposia, and institutional grand rounds.

SPEAKER DISCLOSURES

Consultant:  Allergan, AstraZeneca, IMHealthScience, Prometheus, Sebela, Salix Pharmaceuticals, Shionogi, Torax.

Speaker's Bureau:  Allergan, AstraZeneca, IMHealthScience, Prometheus, Salix Pharmaceuticals, Shionogi, Torax.

Advisory Board Membership:  Allergan, AstraZeneca, Salix Pharmaceuticals, Synergy.

Editorial Board Involvement:  American Journal of Gastroenterology

Author: McMahonPublishing, and UpToDate, Inc.

Book Royalty: SLACK IncorporatedEditor: Clinical Advances in Gastroenterology, Gastroenterology and Hepatoloty (Gastro-Hep Communications), and Springer Science and Business Media

Consultant: Abbott/AbbVie Inc., Actavis, Alaven Pharmaceutical LLC, Celgene, Ferring Pharmaceuticals Inc., Hospira, Inc., Janssen Orthobiotech (Funding to University of PA IBD Fellow Education), Luitpold Pharmaceuticals, Inc./American Regent, Inc., Pfier Inc. (Funding to the University of PA IBD Fellow Education), Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc./Valeant, Santarus, Inc., Shire Pharmaceuticals, Receptos, Takeda (Funding to University of PA IBD Fellow Education), and UCB, Inc.

Honoraria: Clinical Advances in Gastroenterology, Therapeutic Advances in Gastroenterology, Gastroenterology & Hepatology (Gastro-Hep Communications), Ironwood Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc./American Regent, Inc. (CME Programs), Merck (CME Programs), McMahonPublishing, Springer Science and Business Media, UpToDate, and Romark (CME Programs)

Research: Celgene, Janssen Orthobiotech (Funding to University of PA IBD Fellow Education), Salix Pharmaceuticals, Inc./Valeant, Santarus, Inc., Shire Pharmaceuticals, and Receptos, UCB, Inc.

MARIA T. ABREU, MD
Professor of Medicine
Professor of Microbiology and Immunology
Martin Kalser Chair in Gastroenterology
Director, Crohn's & Colitis Center
University of Miami Miller School of Medicine
Miami, Florida

Back to Agenda

Maria T. Abreu, M.D., completed her medical degree at the University of Miami, Miller School of Medicine, where she served as Student Council President and was inducted into the Iron Arrow Honor Society. Her postdoctoral training included an internship and residency in medicine at the Brigham and Women's Hospital in Boston, Massachusetts; clinical and research fellowship in gastroenterology at the University of California, Los Angeles (UCLA), and training in molecular and cancer biology at UCLA. She was an Associate Professor of Medicine with Mount Sinai School of Medicine, NYC, prior to returning to the University of Miami, Miller School of Medicine as Chief of Gastroenterology and Professor of Medicine. She is currently the Director of the Crohn’s and Colitis Center at UM, Professor Medicine and Professor of Microbiology and Immunology.

Dr. Abreu is a Diplomat of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Gastroenterology and a Fellow of the American College of Physicians. Dr. Abreu was elected to the American Society for Clinical Investigation in 2010. She is the council chair of the American Gastroenterological Association (AGA) thru 2018 which is the largest and most academic of gastroenterology societies. As Chair of the Council she leads the group of academicians that plan the annual national meeting and sets policy for AGA. She has served as Chair of the Underrepresented Minorities Committee of the AGA and also as the Chair of the Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section of the AGA Institute Council. She is a member of the AGA Public Affairs and Advisory Committee, the American College of Gastroenterology’s Women's Committee and the Crohn's and Colitis Foundation (CCF). She was the 2014 President for the Board of the Florida Chapter of the CCFA and in 2009 was recognized for her education, support and advocacy for this organization. Dr. Abreu was selected Co-Director of the AGA’s 2011 Spring Postgraduate course and she was also the 2014 President of the Florida Gastroenterology Society. She was recently appointed to the Advisory Board for The Institute for Children and Adolescents with Cancer within the University of Miami Sylvester Comprehensive Cancer Center. Dr. Abreu's most recent appointment is as the Deputy Chair of the International Organization for the Study of Inflammable Bowel Disease (IOIBD), she serves as a Member-at-Large thru 2018 and also serves on the IOIBD Biomarkers Task Force. Dr. Abreu has extensive postgraduate mentoring experience throughout her 21-year research career that makes her intimately aware of key career development issues that physician-scientists face as they transition to become independent investigators. Additionally, she is listed in Castle Connolly as one of America's Top Doctors.

Dr. Abreu's accomplishments in the field of research include an interest in inflammatory bowel disease (IBD) and host-bacterial interactions. Her basic research interests include host-bacterial interactions and the role of toll-like receptor signaling in intestinal inflammation and colon cancer. Her translational work has focused on genotype-phenotype relationships in inflammatory bowel disease and prediction of response to medical therapies. Her GI Research department is committed to the support of IBD patients. Her clinical industry studies assist patients that often come to UM after having been exposed to different treatments without success. Her clinical and research teams offer an opportunity for patients to participate in studies where new medications might provide new treatments that can benefit their quality of life and increase the disease complications and hospitalizations.

As an educator, Dr. Abreu is regularly asked to speak at national and international symposia. Dr. Abreu has authored more than 100 peer-reviewed articles, books, chapters and reviews. Additionally, she has served as an editorial board member for Inflammatory Bowel Diseases and Gastroenterology & Hepatology News; former editor for the Journal of Immunology; former Associate Editor of Journal of Crohn’s & Colitis and ongoing as a reviewer for several other prestigious journals. Dr. Abreu is a frequent speaker at national and international symposia on basic science and clinical topics.

SPEAKER DISCLOSURES

Advisory Board: AbbVie Inc., Allergam Brazikumab, AMGEN ABP 710 Biosimilar Infliximag,Boehringer Ingelheim Pharmaceuticals, Celgene Corporation, MedStar Health, Shire Pharmaceuticals, Roche Pharmaceuticals

Consultant: Celltrion Health Care, Eli Lilly and Company, Focus Medical Communications, Janssen Pharmaceuticals Inc., Pfier Inc., Prometheus Laboratories Inc., Takeda Pharmaceuticals U.S.A., Inc., Theravance Biopharma Us, Inc., and UCB, Inc.

Lecturing: Imedex, Inc., and CME Outfiters

EDWARD V. LOFTUS, JR., MD
Professor of Medicine
Director, Inflammatory Bowel Disease Interest Group
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Back to Agenda

Edward V. Loftus, Jr. earned a medical degree at the University of Pennsylvania and completed a residency in internal medicine at Temple University Health Sciences Center in Philadelphia. He served one year as a general medical officer in the Indian Health Service at Fort Belknap P.H.S. Indian Hospital in Harlem, Montana, and then completed a fellowship in gastroenterology at the Mayo Graduate School of Medicine. He has been on the Mayo Clinic consulting staff since 1995.

Dr. Loftus is a Fellow of the American College of Physicians (ACP), the American College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA). He is a member of several professional societies, including the ACP, AGA, ACG, American Society for Gastrointestinal Endoscopy, and the Crohn’s & Colitis Foundation of America (CCFA). He served as Chair of the Patient Education Committee of the CCFA from 2002 to 2005. He has served on several ACG committees, and has been an abstract reviewer for both AGA and ACG for a number of years. He served as Vice-Chair and then Chair of the Immunology, Microbiology, and Inflammatory Bowel Diseases section of the AGA between 2012 through 2016.

Among Dr. Loftus's awards are the Mayo Department of Medicine Laureate Award (2007) and the CCFA, Minnesota - Dakotas Chapter, Physician of the Year Award (2008). He was elected to membership in the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) in 2008. Dr. Loftus was named Teacher of the Year by the Mayo gastroenterology fellows in 2010-11. He has been named to the Best Doctors in America biannually since 2003 and America’s Top Doctors annually since 2011.He served as Associate Editor of the American Journal of Gastroenterology between 2003 and 2009, and as Associate Editor of Inflammatory Bowel Diseases from 2006 to 2013. He has served on the editorial boards of Gastroenterology and Clinical Gastroenterology, and is currently an editorial board member for the Journal of Crohn's and Colitis.

Dr. Loftus has published over 300 original articles, book chapters, or editorials and more than 400 abstracts, and has lectured extensively on the epidemiology, natural history, diagnosis, and medical management of inflammatory bowel disease.

Dr. Loftus has served as the principal investigator on several funded studies focusing on the epidemiology and natural history of Inflammatory bowel disease.

SPEAKER DISCLOSURES

Grants/Research Support: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, MedImmune, Pfier, Receptos, Robarts Clinical Trials, Seres Therapeutics, Takeda, and UCB Pharma

Consultant: AbbVie, Amgen, Celgene, Celltrion, CVS Caremark, Eli Lilly, Janssen, Napo Pharma, Pfier, Salix, Takeda, and UCB Pharma

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.